---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-202879"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:42:13.594891+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharmaceuticals prices $130M stock/warrant offering; net proceeds ~$121.7M

## Summary
- 8,695,652 shares at $11.50/share and pre-funded warrants for 2,608,922 shares at $11.499/warrant.
- Gross proceeds ~$130M; net proceeds ~$121.7M after underwriting discounts and expenses.
- Offering expected to close August 20, 2024; use proceeds for commercialization and vonoprazan clinical development.
- Joint bookrunners: Evercore ISI, Stifel, Guggenheim; co-managers: H.C. Wainwright, Needham, Craig-Hallum.

## SEC filing metadata
- accession: 0001193125-24-202879
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312524202879/0001193125-24-202879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312524202879/d816262d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-202879
- JSON: https://secwatch.observer/filing/0001193125-24-202879.json
- Plain text: https://secwatch.observer/filing/0001193125-24-202879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.